Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 128

1.

The prognostic value of CXCR4 in acute myeloid leukemia.

Ahn JY, Seo K, Weinberg OK, Arber DA.

Appl Immunohistochem Mol Morphol. 2013 Jan;21(1):79-84. doi: 10.1097/PAI.0b013e3182606f4d.

PMID:
22914607
2.

Overexpression of CXCR4 predicts adverse overall and event-free survival in patients with unmutated FLT3 acute myeloid leukemia with normal karyotype.

Konoplev S, Rassidakis GZ, Estey E, Kantarjian H, Liakou CI, Huang X, Xiao L, Andreeff M, Konopleva M, Medeiros LJ.

Cancer. 2007 Mar 15;109(6):1152-6.

3.

CXC chemokine receptor 4 expression, CXC chemokine receptor 4 activation, and wild-type nucleophosmin are independently associated with unfavorable prognosis in patients with acute myeloid leukemia.

Konoplev S, Lin P, Yin CC, Lin E, Nogueras González GM, Kantarjian HM, Andreeff M, Medeiros LJ, Konopleva M.

Clin Lymphoma Myeloma Leuk. 2013 Dec;13(6):686-92. doi: 10.1016/j.clml.2013.05.013. Epub 2013 Sep 11.

4.

Relationship between CXC chemokine receptor 4 expression and prognostic significance in acute myeloid leukemia.

Cao T, Ye Y, Liao H, Shuai X, Jin Y, Su J, Zheng Q.

Medicine (Baltimore). 2019 Jun;98(23):e15948. doi: 10.1097/MD.0000000000015948.

5.

Risk assessment in patients with acute myeloid leukemia and a normal karyotype.

Bienz M, Ludwig M, Leibundgut EO, Mueller BU, Ratschiller D, Solenthaler M, Fey MF, Pabst T.

Clin Cancer Res. 2005 Feb 15;11(4):1416-24. Erratum in: Clin Cancer Res. 2005 Aug 1;11(15):5659.

6.

CXCR4 Overexpression is a Poor Prognostic Factor in Pediatric Acute Myeloid Leukemia With Low Risk: A Report From the Japanese Pediatric Leukemia/Lymphoma Study Group.

Matsuo H, Nakamura N, Tomizawa D, Saito AM, Kiyokawa N, Horibe K, Nishinaka-Arai Y, Tokumasu M, Itoh H, Kamikubo Y, Nakayama H, Kinoshita A, Taga T, Tawa A, Taki T, Tanaka S, Adachi S.

Pediatr Blood Cancer. 2016 Aug;63(8):1394-9. doi: 10.1002/pbc.26035. Epub 2016 May 2.

PMID:
27135782
7.

CD34 expression predicts an adverse outcome in patients with NPM1-positive acute myeloid leukemia.

Dang H, Chen Y, Kamel-Reid S, Brandwein J, Chang H.

Hum Pathol. 2013 Oct;44(10):2038-46. doi: 10.1016/j.humpath.2013.03.007. Epub 2013 May 21.

PMID:
23701943
8.

Prognostic value of immunophenotyping and gene mutations in elderly patients with acute myeloid leukemia with normal karyotype.

Dang H, Jiang A, Kamel-Reid S, Brandwein J, Chang H.

Hum Pathol. 2013 Jan;44(1):55-61. doi: 10.1016/j.humpath.2012.04.008. Epub 2012 Aug 28.

PMID:
22939316
9.

Prognostic significance of CEBPA mutations in a large cohort of younger adult patients with acute myeloid leukemia: impact of double CEBPA mutations and the interaction with FLT3 and NPM1 mutations.

Green CL, Koo KK, Hills RK, Burnett AK, Linch DC, Gale RE.

J Clin Oncol. 2010 Jun 1;28(16):2739-47. doi: 10.1200/JCO.2009.26.2501. Epub 2010 May 3.

PMID:
20439648
10.

Nucleophosmin gene mutations are predictors of favorable prognosis in acute myelogenous leukemia with a normal karyotype.

Schnittger S, Schoch C, Kern W, Mecucci C, Tschulik C, Martelli MF, Haferlach T, Hiddemann W, Falini B.

Blood. 2005 Dec 1;106(12):3733-9. Epub 2005 Aug 2.

11.

CXCR4 is a prognostic marker in acute myelogenous leukemia.

Spoo AC, Lübbert M, Wierda WG, Burger JA.

Blood. 2007 Jan 15;109(2):786-91. Epub 2006 Aug 3.

12.

The N-terminal CEBPA mutant in acute myeloid leukemia impairs CXCR4 expression.

Kuo YY, Hou HA, Chen YK, Li LY, Chen PH, Tseng MH, Huang CF, Lee FY, Liu MC, Liu CW, Chou WC, Liu CY, Tang JL, Yao M, Tien HF.

Haematologica. 2014 Dec;99(12):1799-807. doi: 10.3324/haematol.2014.107821. Epub 2014 Sep 5.

13.

Normal karyotype acute myeloid leukemia patients with CEBPA double mutation have a favorable prognosis but no survival benefit from allogeneic stem cell transplant.

Ahn JS, Kim JY, Kim HJ, Kim YK, Lee SS, Jung SH, Yang DH, Lee JJ, Kim NY, Choi SH, Minden MD, Jung CW, Jang JH, Kim HJ, Moon JH, Sohn SK, Won JH, Kim SH, Kim DD.

Ann Hematol. 2016 Jan;95(2):301-10. doi: 10.1007/s00277-015-2540-7. Epub 2015 Nov 4. Erratum in: Ann Hematol. 2016 Jan;95(2):363.

PMID:
26537612
14.

CD123 immunohistochemical expression in acute myeloid leukemia is associated with underlying FLT3-ITD and NPM1 mutations.

Rollins-Raval M, Pillai R, Warita K, Mitsuhashi-Warita T, Mehta R, Boyiadzis M, Djokic M, Kant JA, Roth CG.

Appl Immunohistochem Mol Morphol. 2013 May;21(3):212-7. doi: 10.1097/PAI.0b013e318261a342.

PMID:
22914610
15.

Prognostic implications of NPM1 mutations and FLT3 internal tandem duplications in Egyptian patients with cytogenetically normal acute myeloid leukemia.

Shamaa S, Laimon N, Aladle DA, Azmy E, Elghannam DM, Salem DA, Taalab MM.

Hematology. 2014 Jan;19(1):22-30. doi: 10.1179/1607845413Y.0000000085. Epub 2013 Nov 25.

PMID:
23540998
16.

Importance of early detection and follow-up of FLT3 mutations in patients with acute myeloid leukemia.

Colovic N, Tosic N, Aveic S, Djuric M, Milic N, Bumbasirevic V, Colovic M, Pavlovic S.

Ann Hematol. 2007 Oct;86(10):741-7. Epub 2007 Jun 20.

PMID:
17579862
17.

Relation between CXCR-4 expression, Flt3 mutations, and unfavorable prognosis of adult acute myeloid leukemia.

Rombouts EJ, Pavic B, Löwenberg B, Ploemacher RE.

Blood. 2004 Jul 15;104(2):550-7. Epub 2004 Mar 30.

18.

Clinical impact of nucleophosmin mutations and Flt3 internal tandem duplications in patients older than 60 yr with acute myeloid leukaemia.

Scholl S, Theuer C, Scheble V, Kunert C, Heller A, Mügge LO, Fricke HJ, Höffken K, Wedding U.

Eur J Haematol. 2008 Mar;80(3):208-15.

PMID:
18081718
19.

Favorable prognostic impact of NPM1 mutations in older patients with cytogenetically normal de novo acute myeloid leukemia and associated gene- and microRNA-expression signatures: a Cancer and Leukemia Group B study.

Becker H, Marcucci G, Maharry K, Radmacher MD, Mrózek K, Margeson D, Whitman SP, Wu YZ, Schwind S, Paschka P, Powell BL, Carter TH, Kolitz JE, Wetzler M, Carroll AJ, Baer MR, Caligiuri MA, Larson RA, Bloomfield CD.

J Clin Oncol. 2010 Feb 1;28(4):596-604. doi: 10.1200/JCO.2009.25.1496. Epub 2009 Dec 21.

20.

High IDH1 expression is associated with a poor prognosis in cytogenetically normal acute myeloid leukemia.

Ma QL, Wang JH, Wang YG, Hu C, Mu QT, Yu MX, Wang L, Wang DM, Yang M, Yin XF, Chen FF, Lu SS, Chen J, Zhu ZJ, Chen SJ, Jin J.

Int J Cancer. 2015 Sep 1;137(5):1058-65. doi: 10.1002/ijc.29395. Epub 2015 Jan 13.

Supplemental Content

Support Center